- South Korea
- /
- Biotech
- /
- KOSDAQ:A086890
Investors in ISU Abxis (KOSDAQ:086890) from five years ago are still down 20%, even after 17% gain this past week
It's nice to see the ISU Abxis Co., Ltd. (KOSDAQ:086890) share price up 17% in a week. But that doesn't change the fact that the returns over the last five years have been less than pleasing. In fact, the share price is down 20%, which falls well short of the return you could get by buying an index fund.
Although the past week has been more reassuring for shareholders, they're still in the red over the last five years, so let's see if the underlying business has been responsible for the decline.
In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
ISU Abxis became profitable within the last five years. Most would consider that to be a good thing, so it's counter-intuitive to see the share price declining. Other metrics might give us a better handle on how its value is changing over time.
Revenue is actually up 21% over the time period. A more detailed examination of the revenue and earnings may or may not explain why the share price languishes; there could be an opportunity.
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
Take a more thorough look at ISU Abxis' financial health with this free report on its balance sheet.
A Different Perspective
ISU Abxis provided a TSR of 0.5% over the last twelve months. But that was short of the market average. On the bright side, that's still a gain, and it is certainly better than the yearly loss of about 4% endured over half a decade. So this might be a sign the business has turned its fortunes around. It's always interesting to track share price performance over the longer term. But to understand ISU Abxis better, we need to consider many other factors. Even so, be aware that ISU Abxis is showing 1 warning sign in our investment analysis , you should know about...
But note: ISU Abxis may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on South Korean exchanges.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSDAQ:A086890
ISU Abxis
A biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide.
Excellent balance sheet with acceptable track record.
Similar Companies
Market Insights
Community Narratives
